In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Dermira, Inc.
(NASDAQ:DERM), Elanco Animal Health Incorporated (NYSE:ELAN), Ready
Capital Corp (NYSE:RC), Cushman & Wakefield PLC (NYSE:CWK),
BlueLinx Holdings Inc. (NYSE:BXC), and Lydall, Inc. (NYSE:LDL),
including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
DERM DOWNLOAD:
http://Capital-Review.com/register/?so=DERM ELAN DOWNLOAD:
http://Capital-Review.com/register/?so=ELAN RC DOWNLOAD:
http://Capital-Review.com/register/?so=RC CWK DOWNLOAD:
http://Capital-Review.com/register/?so=CWK BXC DOWNLOAD:
http://Capital-Review.com/register/?so=BXC LDL DOWNLOAD:
http://Capital-Review.com/register/?so=LDL
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Dermira,
Inc. (NASDAQ:DERM), Elanco Animal Health Incorporated (NYSE:ELAN),
Ready Capital Corp (NYSE:RC), Cushman & Wakefield PLC
(NYSE:CWK), BlueLinx Holdings Inc. (NYSE:BXC), and Lydall, Inc.
(NYSE:LDL) on a fundamental level and outlines the overall demand
for their products and services in addition to an in-depth review
of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
DERMIRA, INC. (DERM) REPORT OVERVIEW
Dermira's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Dermira reported revenue of $2.24MM vs
$1.34MM (up 67.01%) and analysts estimated basic earnings per share
-$1.70 vs -$1.46. For the twelve months ended December 31st, 2018
vs December 31st, 2017, Dermira reported revenue of $42.34MM vs
$4.54MM (up 832.37%) and analysts estimated basic earnings per
share -$5.27 vs -$7.48. Analysts expect earnings to be released on
May 2nd, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$1.39. The estimated EPS forecast for the next fiscal year is
-$4.33 and is expected to report on February 25th, 2020.
To read the full Dermira, Inc. (DERM) report, download it here:
http://Capital-Review.com/register/?so=DERM
-----------------------------------------
ELANCO ANIMAL HEALTH INCORPORATED (ELAN) REPORT
OVERVIEW
Elanco Animal Health's Recent Financial
Performance
For the twelve months ended December 31st, 2018
vs December 31st, 2017, Elanco Animal Health reported revenue of
$3,066.80MM vs $2,889.00MM (up 6.15%) and analysts estimated basic
earnings per share $0.28 vs -$1.06. Analysts expect earnings to be
released on May 1st, 2019. The report will be for the fiscal period
ending March 31st, 2019. The estimated EPS forecast for the next
fiscal year is $1.29 and is expected to report on February 5th,
2020.
To read the full Elanco Animal Health Incorporated (ELAN)
report, download it here:
http://Capital-Review.com/register/?so=ELAN
-----------------------------------------
READY CAPITAL CORP (RC) REPORT OVERVIEW
Ready Capital's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Ready Capital reported revenue of $46.20MM
vs $36.14MM (up 27.86%) and analysts estimated basic earnings per
share $0.27 vs $0.38 (down 28.95%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Ready Capital reported
revenue of $169.50MM vs $138.31MM (up 22.55%) and analysts
estimated basic earnings per share $1.84 vs $1.38 (up 33.33%).
Analysts expect earnings to be released on May 14th, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.47. The
estimated EPS forecast for the next fiscal year is $1.84 and is
expected to report on March 10th, 2020.
To read the full Ready Capital Corp (RC) report, download it
here:
http://Capital-Review.com/register/?so=RC
-----------------------------------------
CUSHMAN & WAKEFIELD PLC (CWK) REPORT
OVERVIEW
Cushman & Wakefield's Recent Financial
Performance
For the twelve months ended December 31st, 2018
vs December 31st, 2017, Cushman & Wakefield reported revenue of
$8,219.90MM vs $6,923.90MM (up 18.72%) and analysts estimated basic
earnings per share -$1.09 vs -$1.54. Analysts expect earnings to be
released on May 22nd, 2019. The report will be for the fiscal
period ending March 31st, 2019. The estimated EPS forecast for the
next fiscal year is $0.90 and is expected to report on February
26th, 2020.
To read the full Cushman & Wakefield PLC (CWK) report,
download it here:
http://Capital-Review.com/register/?so=CWK
-----------------------------------------
BLUELINX HOLDINGS INC. (BXC) REPORT
OVERVIEW
BlueLinx's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, BlueLinx reported revenue of $672.64MM vs
$433.61MM (up 55.13%) and analysts estimated basic earnings per
share -$1.74 vs $5.90. For the twelve months ended December 31st,
2018 vs December 31st, 2017, BlueLinx reported revenue of
$2,862.85MM vs $1,815.54MM (up 57.69%) and analysts estimated basic
earnings per share -$5.21 vs $6.96. Analysts expect earnings to be
released on May 2nd, 2019. The report will be for the fiscal period
ending March 31st, 2019.
To read the full BlueLinx Holdings Inc. (BXC) report, download
it here:
http://Capital-Review.com/register/?so=BXC
-----------------------------------------
LYDALL, INC. (LDL) REPORT OVERVIEW
Lydall's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Lydall reported revenue of $209.94MM vs
$178.03MM (up 17.92%) and analysts estimated basic earnings per
share $0.42 vs $0.80 (down 47.50%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Lydall reported revenue
of $785.90MM vs $698.44MM (up 12.52%) and analysts estimated basic
earnings per share $2.03 vs $2.89 (down 29.76%). Analysts expect
earnings to be released on May 7th, 2019. The report will be for
the fiscal period ending March 31st, 2019. The reported EPS for the
same quarter last year was $0.67. The estimated EPS forecast for
the next fiscal year is $2.17 and is expected to report on February
24th, 2020.
To read the full Lydall, Inc. (LDL) report, download it here:
http://Capital-Review.com/register/?so=LDL
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024